121 related articles for article (PubMed ID: 10498468)
1. Valacyclovir to prevent cytomegalovirus disease after renal transplantation.
Shapiro ME; Abrams JM
N Engl J Med; 1999 Sep; 341(12):921. PubMed ID: 10498468
[No Abstract] [Full Text] [Related]
2. Prophylaxis of cytomegalovirus infection in renal transplantation.
Ostermann M; MacPhee I; Chang R
Nephrol Dial Transplant; 2001 Nov; 16(11):2276-9. PubMed ID: 11682689
[No Abstract] [Full Text] [Related]
3. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
[No Abstract] [Full Text] [Related]
4. The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation.
Le Meur Y; Mons S; Moesch C; Leroux-Robert C
Nephrol Dial Transplant; 2000 Mar; 15(3):442. PubMed ID: 10692544
[No Abstract] [Full Text] [Related]
5. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem.
Kuypers DR; Vanrenterghem YF
Nephrol Dial Transplant; 1999 Oct; 14(10):2304-8. PubMed ID: 10528649
[No Abstract] [Full Text] [Related]
6. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
7. Lowering immunosuppression is safe and effective to treat altered pattern of CMV infection in renal transplant recipients on valaciclovir prophylaxis.
Anglicheau D; Lautrette A; Scieux C; Thervet E; Martinez F; Flamant M; Morinet F; Legendre C
Transplant Proc; 2002 Nov; 34(7):2826-7. PubMed ID: 12431624
[No Abstract] [Full Text] [Related]
8. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
Fiddian P; Sabin CA; Griffiths PD
J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation.
Santos RD; Brennan DC
J Am Soc Nephrol; 2012 Sep; 23(9):1446-8. PubMed ID: 22878958
[No Abstract] [Full Text] [Related]
11. Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits.
Bertoni E; Rosati A; Zanazzi M; Moscarelli L; Di Maria L; Piperno R; Orsi A; Parri F; Dedola G; Salvadori M
Transplant Proc; 1998 Aug; 30(5):2094. PubMed ID: 9723402
[No Abstract] [Full Text] [Related]
12. Successful use of oral valacyclovir in post-transplant cytomegalovirus infection in renal allograft recipients.
Himmelmann-Jud B; Wüthrich RP; Weinreich T; Binswanger U
Nephrol Dial Transplant; 1998 May; 13(5):1326-7. PubMed ID: 9623588
[No Abstract] [Full Text] [Related]
13. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
Reischig T; Kacer M
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
[TBL] [Abstract][Full Text] [Related]
14. Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients.
Vila A; Guirado LL; Balius A; Díaz M; Baró E; Olaya M; Andrade M; Agraz I; Solá R
Transplant Proc; 1999 Sep; 31(6):2335-6. PubMed ID: 10500605
[No Abstract] [Full Text] [Related]
15. Ganciclovir for cytomegalovirus infection in renal transplant recipients.
Lancet; 1989 Jan; 1(8631):216-7. PubMed ID: 2563118
[No Abstract] [Full Text] [Related]
16. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
17. The economic value of valacyclovir prophylaxis in transplantation.
Squifflet JP; Legendre C
J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary?
Smith SR; Butterly DW; Conlon PJ; Harland RC; Emovon OE
Transplant Proc; 1998 Aug; 30(5):2097-9. PubMed ID: 9723404
[No Abstract] [Full Text] [Related]
19. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
